Pacific Biosciences of California Inc (PACB) (Q3 2026) Earnings Call Highlights: Revenue
Pacific Biosciences (PACB) reported Q3 2026 revenue growth of 6% YoY to $40.6M, with consumables revenue down 2% YoY. Non-GAAP gross margin fell to 36% from 42% due to higher costs. Americas and Asia Pacific revenues declined, while EMEA grew 30%. Cash burn was $32.8M, with Q4 expected to decrease. The company narrowed full-year revenue guidance to $155M-$160M and expects cash flow breakeven in 2028.
How this was made

The 30-second read
Why it matters
The earnings release provides fresh guidance and margin data that were not previously public, making it a primary source of market‑moving information.
Market read
Earnings miss and lowered guidance likely trigger short‑term sell pressure, while long‑term product developments could mitigate downside.
What to watch
The high‑throughput platform slated for 2027 could unlock larger contracts, and the clinical segment now exceeds 20% of revenue.
Background
Pacific Biosciences (PACB) reported its Q3 2026 results, highlighting modest revenue growth, margin compression, and a revised full‑year outlook.
Ticker impact
Q3 2026 earnings released with revenue $40.6M (+6% YoY) and non‑GAAP net loss $32.8M, margin down to 36%, and lowered full‑year guidance.
likely downside as investors price in weaker margins and reduced guidance
Guidance narrowed, margins fell, and cash burn remains high, all negative catalysts for a small‑cap biotech.
Market effects
Signals continued pressure on long‑read sequencing vendors as consumable transition slows revenue.
Americas revenue weakness highlights funding uncertainty for academic research in the US.
May affect investor sentiment toward niche genomics equipment makers worldwide.
Counterpoint
If SparkNext adoption accelerates, long‑term cash burn could improve, offering a buying opportunity at depressed levels.
Key entities
- CEOMark Van Oene
Provided commentary on SparkNext adoption and product roadmap.
- Chief Accounting OfficerBill Meyer
Presented financial results and guidance.

